Medicine prices on the rise again


Medicines and medical pharmaceuticals in the Russian Federation have significantly increased in price in August. This is noted by both manufacturers and representatives of pharmacies. The main reason for the spike in price is the fall of the rouble combined with the high dependence of the Russian market on foreign raw materials and components.

According to the Unified Interdepartmental Information and Statistical System (EMISS), medicines in August of this year rose by an average of 8.4% compared to the same month of 2019. Some positions increased by more than 20% (iodine added 29% over the year, linex – 28%, mercury medical thermometer – 27%), and medicines from the category of drugs for the treatment of blood diseases and antiprotozoal drugs rose almost 2.5 times (by 134% and 124%, respectively).

Some representatives of pharmacy chains, speaking about the reasons for such a rapid increase in the average selling price, proceed from the fact that customers are increasingly giving preference to expensive drugs.

But most manufacturers of drugs and medical devices believe that the main reason for the rise in prices is the growth of the dollar against the ruble amid the extreme dependence of the Russian market on imports. It is also noted that the introduction of mandatory labelling of drugs from July 1, 2020, forcing manufacturers to spend money on additional equipment.

This is not the first “wave” of drug price increases associated with the devaluation of the ruble. According to the results of the last year, the revenue of pharmacies in the first half of 2020 increased by 14%. Despite these successes, according to experts, by the end of this year, prices may rise by another 10%.

Thus, we see that in this difficult period for the people, manufacturers and sellers of medicines not only shift additional costs onto ordinary Russians but also openly profit from them.

Such dishonesty is a characteristic feature of the capitalist system, sharpened to extract profit at any cost.

 

Comments are closed.